title: [Compliance with hormone replacement therapy in menopausal women: results of a two-year prospective French study comparing transdermal treatment with fixed oral combination therapy].
abstract: OBJECTIVE
  To evaluate rates of continuation with hormone replacement therapy (HRT) at 2 years in 2 cohorts of female patients, one of which was treated with a set combination of oral oestradiol valerate and medroxyprogesterone acetate and the other with percutaneous 17 beta-oestradiol gel combined with an oral progestogen selected by the prescribing doctor.
  
  
  METHODS
  A prospective, randomised, open study, including 885 patients followed for 2 years whose 477 were in the oral HRT cohort and 408 were in the dermal cohort. Randomisation was done by group with prescription of the selected HRT for the cohort. The 2 treatment groups were compared using chi(2) tests and Fisher's exact test for qualitative variables, Student's t test or Wilcoxon's test for qualitative variables and Kaplan-Meier survival curves for continuation of HRT, with comparisons using the log-rank test. The prognostic value of baseline parameters on subsequent continuation of HRT was studied using the Cox model (Wald test, odds ratio). RESULTS; Among the 885 treated patients, 711 received the HRT assigned to their cohort (382 in the oral HRT cohort, 329 in the dermal HRT cohort). After 2 years, 77.9% of the patients in the oral HRT cohort and 73.4% of the patients in the dermal HRT cohort were continuing to take their prescribed HRT (P = 0. 076): 37.9% of patients in the oral HRT cohort and 20.2% of patients in the dermal HRT cohort (P < 0.001) continued taking their treatment without any modification.
  
  
  CONCLUSIONS
  Although there was no significant difference in the level of compliance in the 2 groups, it is nonetheless worth noting that the HRT compliance with a sequential fixed estroprogestogen combination was, in this trial, at least equal to that with the free combination of a transdermal estrogen and a progestogen whose nature, dosage and sequence duration are selected by the prescriber. On the other hand, treatment modifications occurred more frequently in the cutaneous HRT group, which is logical as free combination affords to adapt the treatment to each patient.
authors.affiliation: Centre de régulation des naissances et gynécologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France. dserfatyfncgm@aol.com
authors.forename: D
authors.initials: D
authors.lastname: Serfaty
authors.forename: P
authors.initials: P
authors.lastname: de Reilhac
authors.forename: E
authors.initials: E
authors.lastname: Eschwege
authors.forename: V
authors.initials: V
authors.lastname: Ringa
authors.forename: P
authors.initials: P
authors.lastname: Blin
authors.forename: A
authors.initials: A
authors.lastname: Nandeuil
authors.forename: C
authors.initials: C
authors.lastname: Tavera
authors.forename: M
authors.initials: M
authors.lastname: Mathieu
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D010349:Patient Compliance; D011372:Progestins / Q000008:administration & dosage; D011446:Prospective Studies
chemical_list: D004967:Estrogens; D011372:Progestins